公开(公告)号：US09944711B2

公开(公告)日：2018-04-17

申请号：US14990869

申请日：2016-01-08

Applicant: GENMAB A/S

Inventor： Michel De Weers ,  Tim Walseth ,  Jan Van De Winkel ,  Tom Vink ,  Paul Parren

IPC: C07K16/30 ,  A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  G01N33/573

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/76 ,  G01N33/573 ,  G01N2333/91148

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US09714297B2

公开(公告)日：2017-07-25

申请号：US14839514

申请日：2015-08-28

Applicant: GENMAB A/S

Inventor： Sandra Verploegen ,  David P. E. Satijn ,  Rene M. A. Hoet ,  Paul Parren ,  Jan Van De Winkel ,  Vibeke Miller Breinholt ,  Eva Ehrnrooth ,  Ole Baadsgaard ,  Tom Vink ,  Willem Karel Bleeker ,  Mischa Houtkamp ,  Maroeska Oudshoorn ,  Rob N. De Jong

IPC: C07K16/36 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/36 ,  A61K39/395 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US09657107B2

公开(公告)日：2017-05-23

申请号：US14721709

申请日：2015-05-26

Applicant: GENMAB A/S

Inventor： Joost J. Neijssen ,  Bart De Goeij ,  Edward Norbert Van Den Brink ,  Aran Frank Labrijn ,  Rene Hoet ,  Janine Schuurman ,  Paul Parren ,  Jan Van De Winkel

IPC: A61K39/395 ,  C07K16/30 ,  G01N33/574 ,  C07K16/28 ,  A61K45/06 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/3076 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5748 ,  G01N2333/912

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US09540450B2

公开(公告)日：2017-01-10

申请号：US14199391

申请日：2014-03-06

Applicant: GENMAB A/S

Inventor： Jan Van De Winkel ,  Paul Parren ,  Willem Karel Bleeker ,  Klaus Edvardsen ,  Jeroen Lammerts Van Bueren ,  Thomas Valerius ,  Michael Dechant ,  Wencke Weisner ,  Sven Berger

IPC: C07K16/28 ,  C07K16/40 ,  C07K16/44 ,  C07K16/46 ,  G01N33/573 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/573

Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.

Abstract translation: 本发明涉及用于治疗肿瘤的新方法，包括施用双特异性抗体或两种或多种识别相同靶抗原或抗原复合物的非交叉阻断抗体的组合。 特别地，本发明涉及用于诱导补体介导的细胞杀伤治疗肿瘤的方法，所述方法包括向有需要的人共同施用第一抗体和第二抗体，其中所述第一抗体 结合EGFR，所述第二抗体结合EGFR，所述第一和第二抗体是非交叉阻断的，并且所述给药方案使得在肿瘤部位获得CDC。